Alterity Therapeutics, a biotechnology company, has filed its annual report for the fiscal year ended June 30, 2024, with the United States Securities and Exchange Commission. The report does not include specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share. However, it does indicate that the company has complied with the SEC's reporting requirements over the past 12 months and is up to date with its electronic filings. The company's share structure is detailed, with 5,245,115,318 Ordinary Shares outstanding as of the end of the fiscal year. Alterity Therapeutics has also disclosed its employee count, which stands at 10 as of June 30, 2024, a slight decrease from 11 employees in 2023 and 12 in 2022. The workforce is primarily based in...Show More

Alterity Therapeutics, a biotechnology company, has filed its annual report for the fiscal year ended June 30, 2024, with the United States Securities and Exchange Commission. The report does not include specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share. However, it does indicate that the company has complied with the SEC's reporting requirements over the past 12 months and is up to date with its electronic filings. The company's share structure is detailed, with 5,245,115,318 Ordinary Shares outstanding as of the end of the fiscal year. Alterity Therapeutics has also disclosed its employee count, which stands at 10 as of June 30, 2024, a slight decrease from 11 employees in 2023 and 12 in 2022. The workforce is primarily based in Australia, with a smaller presence in the United States. The company's business development is not explicitly detailed in the report, but the maintenance of a directors' and officers' liability insurance policy and a policy for indemnification of directors and officers is noted, which could be indicative of the company's risk management strategies. The report does not provide explicit future plans or strategic initiatives.